US2020276228A1PendingUtilityA1

Immune-modifying nanoparticles for the treatment of inflammatory diseases

70
Assignee: COUR PHARMACEUTICALS DEV COMPANY INCPriority: Mar 13, 2013Filed: May 15, 2020Published: Sep 3, 2020
Est. expiryMar 13, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Daniel R. Getts
A61K 9/14A61P 9/10A61K 31/78A61K 31/765A61K 31/74Y02A50/30A61P 9/00A61K 2039/55555A61P 7/02A61P 29/00A61P 17/00A61P 31/14A61P 3/10A61P 43/00A61P 11/06A61P 31/16A61P 31/04A61P 27/02G01N 33/6893A61P 9/08A61P 17/04A61K 39/39A61K 39/001A61P 31/22A61K 31/00A61P 25/28A61P 31/20A61P 37/08A61P 31/12A61K 39/0005A61P 5/50A61P 35/00A61K 31/01A61P 17/06A61P 1/04A61K 9/0019A61P 37/06G01N 2800/7095A61K 9/146A61P 25/00A61P 19/02A61P 21/02A61P 11/02A61K 9/1647A61P 21/00Y02A50/394A61K 39/00
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising negatively charged poly (lactic-co-glycolic acid) (PLGA) particles, wherein the particles have a diameter ranging from 0.1 μm to 10 μm and a zeta potential ranging from −100 mV to −30 mV, and the particles are free from an additional therapeutic agent. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the diameter is about 0.5 μm. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the diameter ranges from about 0.1 μm to about 1 μm. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the diameter ranges from about 0.3 μm to about 5 μm. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the diameter ranges from about 0.5 μm to about 3 μm. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the diameter ranges from about 0.5 μm to about 1 μm. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the ratio of poly lactic acid to poly glycolic acid in the PLGA particles is about 50:50, about 80:20 or about 90:10. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the ratio of poly lactic acid to poly glycolic acid in the PLGA particles is about 50:50. 
     
     
         9 . The pharmaceutical composition of  claim 1 , comprising a buffer. 
     
     
         10 . The pharmaceutical composition of  claim 1 , comprising an isotonic agent. 
     
     
         11 . The pharmaceutical composition of  claim 1 , comprising a surfactant. 
     
     
         12 . The pharmaceutical composition of  claim 1 , comprising a preservative. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the zeta potential ranges from −75 mV to −40 mV. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the diameter ranges from about 0.5 μm to about 1 μm. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the ratio of poly lactic acid to poly glycolic acid in the PLGA particles is 50:50. 
     
     
         16 . The pharmaceutical composition of  claim 15 , comprising a buffer, an isotonic agent, a surfactant, a preservative, or combinations thereof. 
     
     
         17 . The pharmaceutical composition of  claim 1 , wherein the zeta potential ranges from −40 mV to −30 mV. 
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein the diameter ranges from about 0.5 μm to about 1 μm. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the ratio of poly lactic acid to poly glycolic acid in the PLGA particles is 50:50. 
     
     
         20 . The pharmaceutical composition of  claim 19 , comprising a buffer, an isotonic agent, a surfactant, a preservative, or combinations thereof.

Join the waitlist — get patent alerts

Track US2020276228A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.